Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

Tripathy Discusses Developments in HR+ Breast Cancer

Survival Disparity Analysis Yields Unexpected Findings in mCRPC

CNS Metastases Remain Unmet Need in HER2+ Breast Cancer

Antibody-Drug Conjugate Could Lead to Treatment Advances in Pediatric Neuroblastoma

Dr. Brander Discusses the Frontline Treatment of CLL

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

Brentuximab Vedotin Approved in Europe for CTCL

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor

Related Videos

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

View Conference Coverage

2018 International Lung Cancer Congress

2018 Pan Pacific Lymphoma Conference

2nd Annual Live Medical Crossfire® : Hematologic Malignancies

State of the Science Summit on A Summer of Progress: Updates from ASCO 2018

Online CME Activities

Title	Expiration Date	CME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize Outcomes	Aug 16, 2018	1.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical Management	Aug 25, 2018	1.5